Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
63 hedge funds and large institutions have $104M invested in Merrimack Pharmaceuticals, Inc. in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 6 closing their positions.
126% more call options, than puts
Call options by funds: $3.74M | Put options by funds: $1.66M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
6% more capital invested
Capital invested by funds: $98.5M → $104M (+$5.97M)
3.01% more ownership
Funds ownership: 56.14% → 59.15% (+3%)
2% more funds holding
Funds holding: 62 → 63 (+1)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$2.68M |
| 2 |
CC
Centiva Capital
New York
|
+$2.27M |
| 3 |
ICM
Indaba Capital Management
San Francisco,
California
|
+$1.66M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.01M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$527K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.37M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.07M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$571K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$177K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$136K |
MACK Hedge Fund Activity: Q3 2023 in Review
63 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2023, worth a combined $104M — up 6.1% from $98.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MACK positions and 6 closed out — a net gain of 1 holder — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Western Standard LLC, adding an estimated $2.68M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.37M sold.
- 63 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2023, up from 62 in Q2 2023.
- Funds reported $104M of Merrimack Pharmaceuticals, Inc. stock for Q3 2023, up 6.1% quarter-over-quarter.
- 7 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2023 and 6 closed out, a net change of +1 holder.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2023 was Western Standard LLC, an estimated $2.68M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2023 was Nantahala Capital Management, an estimated $1.37M sold.
Based on aggregated 13F filings for Q3 2023.